Figure 2.

The effect of brain tumour-derived EVs on immune cells. EVs derived from primary brain tumour cells can induce an M2 phenotype in microglia and decrease the cytotoxicity of the CD8 + T cells. Metastatic brain tumour EVs can activate microglia through the TLR receptor.